GYRE vs VRTX
GYRE: A China-based biopharmaceutical company generating revenue from approved antifibrotic treatments while advancing late-stage candidates for liver and other organ fibrosis in the U.S. market. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | GYRE | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $6.13 | $479.00 | |
| Market cap as of 2026-07-31 | $653M | $121.6B | |
| P/E as of 2026-07-31 | 129.96 | 27.74 | VRTX lower |
| PEG as of 2026-07-31 | n/a | 2.31 | |
| Net margin as of 2026-07-31 | -5.4% | +35.5% | VRTX higher |
| Gross margin as of 2026-07-31 | +95.1% | +86.2% | GYRE higher |
| Operating margin as of 2026-07-31 | -0.1% | +38.3% | VRTX higher |
| ROE as of 2026-07-31 | -6.3% | +23.9% | VRTX higher |
| ROA as of 2026-07-31 | -4.0% | +17.2% | VRTX higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.01 | GYRE lower |
| Revenue growth (YoY) as of 2026-07-31 | +16.3% | +10.1% | GYRE higher |
| Revenue CAGR (3y) SEC XBRL | +4.5% | +10.4% | VRTX higher |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-31 | 2.38 | 0.30 | |
| 1-year return as of 2026-07-27 close | -19.8% | +2.0% | VRTX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.